Italy Glp-1 Receptor Agonist Market Size & Outlook
Italy glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
Italy glp-1 receptor agonist market highlights
- The Italy glp-1 receptor agonist market generated a revenue of USD 440.3 million in 2023 and is expected to reach USD 2,112.4 million by 2030.
- The Italy market is expected to grow at a CAGR of 25.1% from 2024 to 2030.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 440.3 million |
| Market revenue in 2030 | USD 2,112.4 million |
| Growth rate | 25.1% (CAGR from 2023 to 2030) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Other Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, Italy accounted for 1.2% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- Norway is the fastest growing regional market in Europe and is projected to reach USD 1,225.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Italy glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 46.1% in 2023. Horizon Databook has segmented the Italy glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, mounjaro (tirzepatide), rybelsus (oral semaglutide), saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
The healthcare system in Italy is well-established, which is contributing to the growth of GLP-1 receptor agonist market. The country provides universal healthcare coverage benefits to its citizens, but the Italian government adopts special measures to ensure healthcare accessibility to vulnerable groups, such as individuals suffering from various target diseases.
Italy has seen a significant increase in the prevalence of diabetes and obesity, which are major risk factors for type 2 diabetes. The International Diabetes Federation reports that approximately 5.5% of the adult population in Italy has diabetes, with many more individuals at risk.
This growing health crisis has created a higher demand for effective treatments, including GLP-1 receptor agonists, which are known for their efficacy in managing blood sugar levels and promoting weight loss. Italy's GLP-1 receptor agonist market is experiencing robust growth, driven by the presence of local players and increasing research activities in the field of peptide-based drug development.
Reasons to subscribe to Italy glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Italy glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into Italy glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Italy glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
Italy GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
